Neurobiology of reward-related learning

Galaj, Ewa; Ranaldi, Robert

doi:10.1016/j.neubiorev.2021.02.007

Cited by 16 publications

(21 citation statements)

References 179 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A comparison of these results with those obtained using high-performance liquid chromatography analysis showed a similar level of DA detected from N2a cells, which is 4.9 ± 0.5 pM . Further experiments containing either harpagide, a natural product known to promote synaptic DA release, , or 6-hydroxydopamine (6-OHDA), , a neurotoxicant that is detrimental to dopaminergic neurons, were performed to verify the capacity of N7-P for detecting DA released from cells under these treatments. We treated N2a cells with either harpagide or 6-OHDA and used N7-P integrated biosensor to measure corresponding DA levels (Supporting Information 1.6 and).…”

Section: Resultsmentioning

confidence: 65%

Microfluidic Biosensor Decorated with an Indium Phosphate Nanointerface for Attomolar Dopamine Detection

et al. 2023

View full text Add to dashboard Cite

Developing functional materials that directly integrate into miniaturized devices for sensing applications is essential for constructing the next-generation point-of-care system. Although crystalline structure materials such as metal organic frameworks are attractive materials exhibiting promising potential for biosensing, their integration into miniaturized devices is limited. Dopamine (DA) is a major neurotransmitter released by dopaminergic neurons and has huge implications in neurodegenerative diseases. Integrated microfluidic biosensors capable of sensitive monitoring of DA from mass-limited samples is thus of significant importance. In this study, we developed and systematically characterized a microfluidic biosensor functionalized with the hybrid material composed of indium phosphate and polyaniline nanointerfaces for DA detection. Under the flowing operation, this biosensor displays a linear dynamic sensing range going from 10 −18 to 10 −11 M and a limit of detection (LOD) value of 1.83 × 10 −19 M. In addition to the high sensitivity, this microfluidic sensor showed good selectivity toward DA and high stability (>1000 cycles). Further, the reliability and practical utility of the microfluidic biosensor were demonstrated using the neuro-2A cells treated with the activator, promoter, and inhibiter. These promising results underscore the importance and potential of microfluidic biosensors integrated with hybrid materials as advanced biosensors systems.

show abstract

Section: Resultsmentioning

confidence: 65%

Microfluidic Biosensor Decorated with an Indium Phosphate Nanointerface for Attomolar Dopamine Detection

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Developing an addiction includes the pathological activation of the natural reward and reinforcement system in the brain [ 36 ]. This system is responsible for judging external stimuli and giving them either a positive or a negative value, depending on whether they have a beneficial or a detrimental outcome for the individual and the species [ 37 ]. Through Pavlovian conditioning, former neutral stimuli are linked to an evaluation regarding their impact on well-being and survival.…”

Section: Addictive Reward Mechanisms In Gdmentioning

confidence: 99%

Drug-Induced Gambling Disorder: Epidemiology, Neurobiology, and Management

Wolfschlag

Håkansson

2023

Pharm Med

View full text Add to dashboard Cite

Problematic gambling has been suggested to be a possible consequence of dopaminergic medications used mainly in neurological conditions, i.e. pramipexole and ropinirole, and possibly by one antipsychotic compound, aripiprazole. Patients with Parkinson’s disease, restless legs syndrome and other conditions potentially treated with dopamine agonists, as well as patients treated for psychotic disorders, are vulnerable patient groups with theoretically increased risk of developing gambling disorder (GD), for example due to higher rates of mental ill-health in these groups. The aim of the present paper is to review the epidemiological, clinical, and neurobiological evidence of the association between dopaminergic medications and GD, and to describe risk groups and treatment options. The neurobiology of GD involves the reward and reinforcement system, based mainly on mesocorticolimbic dopamine projections, with the nucleus accumbens being a crucial area for developing addictions to substances and behaviors. The addictive properties of gambling can perhaps be explained by the reward uncertainty that activates dopamine signaling in a pathological manner. Since reward-related learning is mediated by dopamine, it can be altered by dopaminergic medications, possibly leading to increased gambling behavior and a decreased impulse control. A causal relationship between the medications and GD seems likely, but the molecular mechanisms behind this association have not been fully described yet. More research is needed in order to fully outline the clinical picture of GD developing in patient groups with dopaminergic medications, and data are needed on the differentiation of risk in different compounds. In addition, very few interventional studies are available on the management of GD induced by dopaminergic medications. While GD overall can be treated, there is need for treatment studies testing the effectiveness of tapering of the medication or other gambling-specific treatment modalities in these patient groups.

show abstract

Section: Barriers and Strategies To Adopt And Maintain Physical Activ...mentioning

confidence: 99%

“…9,38 Importantly, animal and human studies have shown that activation of the ventral tegmental area from hedonic stimuli, such as food and social connection, results in phasic dopamine release to the nucleus accumbens. 39,40 Therefore, motivation for PA may also be increased through social and hedonic experiences (eg, enjoying exercising with a group of people). As such, when promoting adoption of PA among people with schizophrenia, social rewards could be facilitated by playing a person's favourite music in a welcoming environment either in groups of people who share similar experiences or individually, depending on the preference, with a facilitator who employs person-centred and inclusive approaches.…”

Section: Reward Prediction Errormentioning

confidence: 99%

Biopsychology of Physical Activity in People with Schizophrenia: An Integrative Perspective on Barriers and Intervention Strategies

Arnautovska¹,

Kesby²,

Korman³

et al. 2022

NDT

View full text Add to dashboard Cite

People with severe mental illness such as schizophrenia experience high physical comorbidity, leading to a 15–20-year mortality gap compared with the general population. Lifestyle behaviours such as physical activity (PA) play important roles in the quest to bridge this gap. Interventions to increase PA engagement in this population have potential to be efficacious; however, their effectiveness can be hindered by low participant engagement, including low adherence and high drop-out, and by implementation of interventions that are not designed to compensate for the cognitive and motivational impairments characteristic for this group. Moreover, and importantly, the negative symptoms of schizophrenia are associated with neurobiological changes in the brain, which—based on principles of biopsychology—can contribute to poor motivation and impaired decision-making processes and behavioural maintenance. To increase PA levels in people with schizophrenia, better understanding of these neurological changes that impact PA engagement is needed. This has the potential to inform the design of interventions that, through enhancement of motivation, could effectively increase PA levels in this specific population. Incorporating strategies that address the dopamine dysregulation associated with schizophrenia, such as boosting the role of reward and self-determined motivation, may improve long-term PA maintenance, leading to habitual PA. Consideration of motivation and behavioural maintenance is also needed to impart health benefits such as prevention of chronic disease, which is associated with currently low PA levels in this high metabolic risk population. Taking a biopsychological perspective, we outline the neural pathways involved in motivation that are impacted by schizophrenia and propose strategies for promoting motivation for and PA engagement from adoption to habit formation.

show abstract

Neurobiology of reward-related learning

Cited by 16 publications

References 179 publications

Microfluidic Biosensor Decorated with an Indium Phosphate Nanointerface for Attomolar Dopamine Detection

Microfluidic Biosensor Decorated with an Indium Phosphate Nanointerface for Attomolar Dopamine Detection

Drug-Induced Gambling Disorder: Epidemiology, Neurobiology, and Management

Biopsychology of Physical Activity in People with Schizophrenia: An Integrative Perspective on Barriers and Intervention Strategies

Contact Info

Product

Resources

About